Dalvance (Dalbavancin HCl) Patent Expiration, LOE Window & CMS Spending
Dalvance (Dalbavancin HCl) by AbbVie: FDA Orange Book LOE 2028-05-23, 0 AB generics, $40.8M 2024 CMS Part D & Medicaid spend, and $1,779 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AbbVie |
| FDA Application & Pathway | N021883 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2028-05-23 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $40.8M |
| 2024 Medicare Part D Spend | $17.9M |
| 2024 Medicaid Spend | $23.0M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,779 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.